TABLE 4.

In vitro activities of antimicrobial agents against gram-positive aerobic organisms

Organism (no. of isolates)MIC50/MIC90 (μg/ml [% susceptible])a
ETPP/TA/CCFLCIPLVXMXFDOXCMT/S
Corynebacterium amycolatum (49)2/>16 (69)≤2/>32 (78)≤1/>8 (78)≤2/>32 (55)8/>8 (27)8/>8 (27)2/>4 (57)≤2/16 (80)8/>8 (10)2/>4 (51)
Corynebacterium spp. and other non-spore-forming gram-positive rodsb (120)≤0.25/2 (93)≤2/>32 (78)≤1/4 (91)≤2/>32 (74)4/>8 (50)2/>8 (54)0.5/>4 (74)≤2/8 (87)8/>8 (30)4/>4 (49)
Enterococcus spp.c (155)8/16 (10)≤2/>32 (97)≤1/≤1 (99)>32/>32 (5)1/>8 (68)1/>8 (77)0.5/>4 (80)4/8 (63)>8/>8 (1)≤0.5/4 (90)
Staphylococcus aureus, Ox-Rd (49)4/>16 (NIe)8/32 (NI)8/>8 (NI)>32/>32 (NI)>8/>8 (12)>8/>8 (16)4/>4 (16)≤2/≤2 (94)>8/>8 (47)≤0.5/≤0.5 (90)
S. aureus, Ox-Sf (169)≤0.25/≤0.25 (100)≤2/≤2 (100)≤1/≤1 (100)≤2/4 (99)≤0.5/1 (94)≤0.5/≤0.5 (96)≤0.25/≤0.25 (95)≤2/≤2 (95)≤0.25/≤0.25 (98)≤0.5/≤0.5 (98)
S. epidermidis (89)2/8 (87)≤2/≤2 (97)≤1/2 (99)16/32 (37)≤0.5/>8 (54)≤0.5/8 (57)≤0.25/2 (63)≤2/8 (90)≤0.25/>8 (89)≤0.5/>4 (67)
S. haemolyticus (22)2/>16 (68)≤2/>32 (68)≤1/>8 (68)>32/>32 (14)>8/>8 (18)8/>8 (23)1/>4 (23)≤2/32 (55)≤0.25/>8 (77)≤0.5/>4 (68)
S. lugdunensis (23)≤0.25/≤0.25 (100)≤2/≤2 (100)≤1/≤1 (100)4/16 (83)≤0.5/≤0.5 (100)≤0.5/≤0.5 (100)≤0.25/≤0.25 (100)≤2/≤2 (100)≤0.25/≤0.25 (91)≤0.5/≤0.5 (100)
Coagulase-negative Staphylococcus spp.g (44)0.5/4 (93)≤2/≤2 (98)≤1/2 (100)≤2/>32 (77)≤0.5/>8 (80)≤0.5/>8 (82)≤0.25/4 (82)≤2/4 (96)≤0.25/>8 (84)≤0.5/1 (91)
Streptgcoccus spp.h (173)≤0.25/≤0.25 (100)≤2/≤ (100)≤1/≤1 (99)≤2/8 (93)≤0.5/4 (71)≤0.5/2 (97)≤0.25/0.5 (97)8/16 (40)≤.25/>8 (90)≤0.5/≤0.5 (95)
  • a ETP, ertapenem; P/T, piperacillin-tazobactam; A/C, amoxicillin-clavulanic acid; CFL, cephalexin; CIP, ciprofloxacin; LVX, levofloxacin; MXF, moxifloxacin; DOX, doxycycline; CM, clindamycin; T/S, trimethoprim-sulfamethoxazole.

  • b Corynebacterium striatum (n = 31), Corynebacterium accolens (n = 1), Corynebacterium aurimucosum (n = 5), Corynebacterium glucuronolyticum (n = 2), Corynebacterium jeikeium (n = 5), Corynebacterium minutissimum (n = 1), Corynebacterium pseudodiphtheriticum (n = 1), “Corynebacterium pseudogenitalium” (n = 2), Corynebacterium pseudotuberculosis (n = 1), Corynebacterium simulans (n = 4), Corynebacterium tuberculostearicum (n = 7), Corynebacterium urealyticum (n = 1), Corynebacterium xerosis (n = 4), Corynebacterium spp. (n = 2), Dermabacter hominis (n = 15), Actinobaculum massiliae (n = 1), Actinomyces neuii subsp. anitratus (n = 2), A. neuii subsp. neuii (n = 1), A. turicensis (n = 2), Arcanobacterium bernardiae (n = 5), Arcanobacterium hemolyticum (n = 3), Arthrobacter albus (n = 2), Arthrobacter creatinolyticus (n = 1), Bacillus cereus (n = 2), Bacillus pumilus (n = 2), Bacillus sp. (n = 1), Bifidobacterium urinalis (n = 1), Brachybacterium sp. (n = 1), Brevibacterium lutoleum (n = 1), Brevibacterium otitidis (n = 1), Brevibacterium spp. (n = 2), Lactobacillus gasseri (n = 1), Lactobacillus jensenii (n = 1), Microbacterium oxydans (2), Paenibacillus sp. (n = 1), Propionibacterium acnes (n = 1) and Propionibacterium avidum (n = 1) (both aerobic), “Zimmermannella bifida” (n = 1), and gram-positive bacilli with no sequence match (n = 2).

  • c Enterococcus faecalis (n = 139), E. avium (n = 3), E. canis (n = 2), E. casseliflavus (n = 1), E. faecium (n = 5), E. gallinarum (n = 4), and Enterococcus sp. (n = 1).

  • d Ox-S, oxacillin sensitive.

  • e NI, no interpretation.

  • f Ox-R, oxacillin resistant.

  • g Staphylococcus. auricularis (n = 1), S. capitis (n = 2), S. caprae (n = 3), S. cohnii (n = 4), S. hominis (n = 5), S. schleiferi (n = 1), S. sciuri (n = 9), S. simulans (n = 12), S. warneri (n = 4), S. xylosus (n = 1), and Staphylococcus spp. with no sequence match (n = 2).

  • h Streptococcus agalactiae (n = 85), S. anginosus (n = 17), S. bovis (n = 1), S. canis (n = 1), S. constellatus (n = 2), S. dysgalactiae subsp. equisimilis (n = 19). S. gordonii (n = 1), S. infantarius (n = 1), S. mitis group (n = 41), S. minor (n = 1), S. pyogenes (n = 3), and S. salivarius (n = 1).